Evidence map›Paper›PMID 37040185›Full record

ArticleJCI insight2023

Cytokine storm-based mechanisms for extrapulmonary manifestations of SARS-CoV-2 infection.

Maria Del Nogal Avila, Ranjan Das, Joubert Kharlyngdoh, Eduardo Molina-Jijon, Hector Donoro Blazquez, Stéphanie Gambut, Michael Crowley, David K Crossman, Rasheed A Gbadegesin, Sunveer S Chugh and 5 more

Open access · goldAbstract read
In one paragraph

Article in JCI insight, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Serum Factors in Primary Podocytopathies.Antibodies (Basel, Switzerland) · 2025
    Review
  7. Article
  8. Article
  9. "Idiopathic" minimal change nephrotic syndrome: a podocyte mystery nears the end.American journal of physiology. Renal physiology · 2023
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Maria Del Nogal AvilaGlomerular Disease Therapeutics Laboratory, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Ranjan DasGlomerular Disease Therapeutics Laboratory, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Joubert KharlyngdohGlomerular Disease Therapeutics Laboratory, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Eduardo Molina-JijonGlomerular Disease Therapeutics Laboratory, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Hector Donoro BlazquezGlomerular Disease Therapeutics Laboratory, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Stéphanie GambutGlomerular Disease Therapeutics Laboratory, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Michael CrowleyGenomics Core Lab, University of Alabama at Birmingham, Birmingham, Alabama, USA.
David K CrossmanGenomics Core Lab, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Rasheed A GbadegesinDivision of Nephrology, Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA.
Sunveer S ChughGlomerular Disease Therapeutics Laboratory, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Sunjeet S ChughGlomerular Disease Therapeutics Laboratory, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Carmen Avila-CasadoDepartment of Anatomical Pathology, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
Camille MacéGlomerular Disease Therapeutics Laboratory, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Lionel C ClementGlomerular Disease Therapeutics Laboratory, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Sumant S ChughGlomerular Disease Therapeutics Laboratory, Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
Rush University Medical Center · USUniversity of Alabama at Birmingham · USDuke Medical Center · USUniversity of Toronto · CA

Funding

Investigation of non-HIV Collapsing GlomerulopathyR01DK111102 · NIDDK · RUSH UNIVERSITY MEDICAL CENTER · PI CHUGH, SUMANT SINGH · 2016 to 2020
$2.8M
ZHX2 in Podocyte DiseaseR01DK109713 · NIDDK · RUSH UNIVERSITY MEDICAL CENTER · PI CHUGH, SUMANT SINGH · 2016 to 2020
$2.7M
Soluble mediators of relapseR01DK128203 · NIDDK · RUSH UNIVERSITY MEDICAL CENTER · PI CHUGH, SUMANT SINGH · 2021 to 2025
$2.7M
Covid 19 cytokine stormR01DK129522 · NIDDK · RUSH UNIVERSITY MEDICAL CENTER · PI CHUGH, SUMANT SINGH · 2021 to 2024
$2.4M
Kidney PCSK9 in nephrotic syndromeR01DK126926 · NIDDK · RUSH UNIVERSITY MEDICAL CENTER · PI CLEMENT, LIONEL CLAUDIUS · 2021 to 2024
$1.4M
Covid-19 induced worsening of glomerular diseasesR01DK133330 · NIDDK · RUSH UNIVERSITY MEDICAL CENTER · PI Camille Emilie Adeline Mace · 2023 to 2026
$1.3M
Investigation of Nephrotic SyndromeK01DK096127 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CLEMENT, LIONEL CLAUDIUS · 2012 to 2016
$761k
NIDDK NIH HHS K01 DK096127NIDDK NIH HHS R01 DK109713NIDDK NIH HHS R01 DK111102NIDDK NIH HHS R01 DK126926NIDDK NIH HHS R01 DK128203NIDDK NIH HHS R01 DK129522NIDDK NIH HHS R01 DK133330
6 · The paper itself

Abstract

Viral illnesses like SARS-CoV-2 have pathologic effects on nonrespiratory organs in the absence of direct viral infection. We injected mice with cocktails of rodent equivalents of human cytokine storms resulting from SARS-CoV-2/COVID-19 or rhinovirus common cold infection. At low doses, COVID-19 cocktails induced glomerular injury and albuminuria in zinc fingers and homeoboxes 2 (Zhx2) hypomorph and Zhx2+/+ mice to mimic COVID-19-related proteinuria. Common Cold cocktail induced albuminuria selectively in Zhx2 hypomorph mice to model relapse of minimal change disease, which improved after depletion of TNF-α, soluble IL-4Rα, or IL-6. The Zhx2 hypomorph state increased cell membrane to nuclear migration of podocyte ZHX proteins in vivo (both cocktails) and lowered phosphorylated STAT6 activation (COVID-19 cocktail) in vitro. At higher doses, COVID-19 cocktails induced acute heart injury, myocarditis, pericarditis, acute liver injury, acute kidney injury, and high mortality in Zhx2+/+ mice, whereas Zhx2 hypomorph mice were relatively protected, due in part to early, asynchronous activation of STAT5 and STAT6 pathways in these organs. Dual depletion of cytokine combinations of TNF-α with IL-2, IL-13, or IL-4 in Zhx2+/+ mice reduced multiorgan injury and eliminated mortality. Using genome sequencing and CRISPR/Cas9, an insertion upstream of ZHX2 was identified as a cause of the human ZHX2 hypomorph state.

Indexed as

Common ColdCOVID-19AlbuminuriaAnimalsCytokine Release SyndromeHomeodomain ProteinsHumansMiceSARS-CoV-2Transcription FactorsTumor Necrosis Factor-alphaHomeodomain ProteinsTranscription FactorsTumor Necrosis Factor-alphaZHX2 protein, humanChronic kidney diseaseCytokinesNephrology

Identifiers

PMID37040185
PMCPMC10322692
OpenAlexW4364352156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.